ArticleJournal of acquired immune deficiency syndromes (1999)2011
Serologic responses to pneumocystis proteins in HIV patients with and without Pneumocystis jirovecii pneumonia.
Article in Journal of acquired immune deficiency syndromes (1999), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00869544 (Pneumocystis in Pathogenesis of HIV-associated Emphysema), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pneumocystis in Pathogenesis of HIV-associated Emphysema
Who cites it
25 citing papers in PubMed, 32 citations in OpenAlex.
- Development of a vaccine construct againstNAR genomics and bioinformatics · 2025Article
- Experimental Pneumocystis infection in dexamethasone immunosuppressed macaques.Medical mycology · 2025Article
- Protective efficacy of a 'pan-fungal' vaccination strategy against experimentalFrontiers in immunology · 2025Article
- Immunogenicity and protective efficacy of a pan-fungal vaccine in preclinical models of aspergillosis, candidiasis, and pneumocystosis.PNAS nexus · 2022Article
- The first detection of Pneumocystis jirovecii in asthmatic patients post-COVID-19 in Jordan.Bosnian journal of basic medical sciences · 2022Article
- A therapeutic vaccine strategy to preventFrontiers in immunology · 2022Article
- Immune Response inJournal of fungi (Basel, Switzerland) · 2021Review
- Relationship ofBMJ open respiratory research · 2021Article
- Review
- Detection of anti-Pneumocystis jirovecii antibodies in human serum using a recombinant synthetic multi-epitope kexin-based antigen.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Observational
- Development of a Gold Nanoparticle-Based Lateral-Flow Immunoassay forFrontiers in microbiology · 2019Article
- Immunization withHuman vaccines & immunotherapeutics · 2019Article
- A Molecular Window into the Biology and Epidemiology of Pneumocystis spp.Clinical microbiology reviews · 2018Review
- Overcoming Hurdles to Development of a Vaccine against Pneumocystis jirovecii.Infection and immunity · 2017Article
- An Emerging Role of B Cell Immunity in Susceptibility to Pneumocystis Pneumonia.American journal of respiratory cell and molecular biology · 2017Article
- Article
- Serological diagnosis of pneumocystosis: production of a synthetic recombinant antigen for immunodetection of Pneumocystis jirovecii.Scientific reports · 2016Article
- Vaccine-Induced Immunogenicity and Protection Against Pneumocystis Pneumonia in a Nonhuman Primate Model of HIV and Pneumocystis Coinfection.The Journal of infectious diseases · 2016Article
- CD4(+) T-Cell-Independent Secondary Immune Responses to Pneumocystis Pneumonia.Frontiers in immunology · 2016Article
- Pneumocystis jirovecii--from a commensal to pathogen: clinical and diagnostic review.Parasitology research · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundImmune responses to Pneumocystis jirovecii are not well understood in HIV infection, but antibody responses to proteins may be useful as a marker of Pneumocystis risk or presence of Pneumocystis pneumonia (PcP).
designRetrospective analysis of a prospective cohort.
methodsEnzyme-linked immunosorbent assays of antibodies to recombinant Pneumocystis proteins of major surface glycoprotein fragments (MsgC1, C3, C8, and C9) and of antibody titers to recombinant kexin protein (KEX1) were performed on 3 sequential serum samples up to 18 months before and 3 samples after first AIDS-defining illness from Multicenter AIDS Cohort Study participants and compared between those who had PcP or a non-PcP AIDS-defining illness.
resultsFifty-four participants had PcP and 47 had a non-PcP AIDS-defining illness. IgG levels to MsgC fragments were similar between groups before first AIDS-defining illness, but the PcP group had higher levels of IgG to MsgC9 (median units/mL 50.2 vs. 22.2, P = 0.047) post-illness. Participants with PcP were more likely to have an increase in MsgC3 [odds ratio (OR): 3.9, P = 0.02], MsgC8 (OR: 5.5, P = 0.001), and MsgC9 (OR: 4.0, P = 0.007). The PcP group was more likely to have low KEX1 IgG before development of PcP (OR: 3.6, P = 0.048) independent of CD4 cell count and to have an increase in high IgG titers to KEX1 after PcP.
conclusionsHIV-infected individuals develop immune responses to both Msg and kexin proteins after PcP. Low KEX1 IgG titers may be a novel marker of future PcP risk before CD4 cell count has declined below 200 cells per microliter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.